Hepatocellular carcinoma: Are we making progress?ZHU, Andrew X.Cancer investigation. 2003, Vol 21, Num 3, pp 418-428, issn 0735-7907, 11 p.Article

Development of Sorafenib and Other Molecularly Targeted Agents in Hepatocellular CarcinomaZHU, Andrew X.Cancer. 2008, Vol 112, Num 2, pp 250-259, issn 0008-543X, 10 p.Article

Targeting the epidermal growth factor receptor in metastatic colorectal cancerNG, Kimmie; ZHU, Andrew X.Critical reviews in oncology/hematology. 2008, Vol 65, Num 1, pp 8-20, issn 1040-8428, 13 p.Article

Molecularly Targeted Therapy for Advanced Hepatocellular Carcinoma in 2012: Current Status and Future PerspectivesZHU, Andrew X.Seminars in oncology. 2012, Vol 39, Num 4, pp 493-502, issn 0093-7754, 10 p.Article

Development of Molecularly Targeted Therapies in Biliary Tract Cancers: Reassessing the Challenges and OpportunitiesZHU, Andrew X; HEZEL, Aram F.Hepatology (Baltimore, Md.). 2011, Vol 53, Num 2, pp 695-704, issn 0270-9139, 10 p.Article

Metabolic Syndrome and Hepatocellular Carcinoma: Two Growing Epidemics With a Potential LinkSIEGEL, Abby B; ZHU, Andrew X.Cancer. 2009, Vol 115, Num 24, pp 5651-5661, issn 0008-543X, 11 p.Article

Targeting the HGF/c-MET Pathway in Hepatocellular CarcinomaGOYAL, Lipika; MUZUMDAR, Mandar D; ZHU, Andrew X et al.Clinical cancer research (Print). 2013, Vol 19, Num 9, pp 2310-2318, issn 1078-0432, 9 p.Article

Genetics of Biliary Tract Cancers and Emerging Targeted TherapiesHEZEL, Aram F; DESHPANDE, Vikram; ZHU, Andrew X et al.Journal of clinical oncology. 2010, Vol 28, Num 21, pp 3531-3540, issn 0732-183X, 10 p.Article

Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and SunitinibLIPWORTH, Adam D; ROBERT, Caroline; ZHU, Andrew X et al.Oncology. 2009, Vol 77, Num 5, pp 257-271, issn 0030-2414, 15 p.Article

Targeting Fibroblast Growth Factor Receptor Signaling in Hepatocellular CarcinomaCHENG, Ann-Lii; SHEN, Ying-Chun; ZHU, Andrew X et al.Oncology. 2011, Vol 81, Num 5-6, pp 372-380, issn 0030-2414, 9 p.Article

Combined modality treatment for rectal cancerZHU, Andrew X; WILLETT, Christopher G.Seminars in oncology. 2005, Vol 32, Num 1, pp 103-112, issn 0093-7754, 10 p.Article

Phase-II Study of Gemcitabine and Cisplatin in Patients with Metastatic Biliary and Gallbladder CancerMEYERHARDT, Jeffrey A; ZHU, Andrew X; STUART, Keith et al.Digestive diseases and sciences. 2008, Vol 53, Num 2, pp 564-570, issn 0163-2116, 7 p.Article

Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancerZHU, Andrew X; CLARK, Jeffrey W; ZHANG, Joshua et al.Cancer chemotherapy and pharmacology. 2007, Vol 59, Num 3, pp 285-293, issn 0344-5704, 9 p.Article

A man with a painful bone mass and lesions in the liverZHU, Andrew X; D'ANDREA, Alan D; SAHANI, Dushyant V et al.The New England journal of medicine. 2006, Vol 354, Num 17, pp 1828-1837, issn 0028-4793, 10 p.Article

A man with esophageal cancer and nausea, vomiting, and intractable hiccupsKRAKAUER, Eric L; ZHU, Andrew X; BOUNDS, Brenna C et al.The New England journal of medicine. 2005, Vol 352, Num 8, pp 817-825, issn 0028-4793, 9 p.Article

Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic CholangiocarcinomaBORGER, Darrell R; GOYAL, Lipika; YEN, Katharine et al.Clinical cancer research (Print). 2014, Vol 20, Num 7, pp 1884-1890, issn 1078-0432, 7 p.Article

MDM2 Promoter Polymorphism and Pancreatic Cancer Risk and PrognosisASOMANING, Kofi; REID, Amy E; CHRISTIANI, David C et al.Clinical cancer research. 2008, Vol 14, Num 12, pp 4010-4015, issn 1078-0432, 6 p.Article

A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumorsKULKE, Matthew H; BINGYAN WU; RYAN, David P et al.Digestive diseases and sciences. 2006, Vol 51, Num 6, pp 1033-1038, issn 0163-2116, 6 p.Article

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinomaZHU, Andrew X; BLASZKOWSKY, Lawrence S; STUART, Keith et al.Journal of clinical oncology. 2006, Vol 24, Num 12, pp 1898-1903, issn 0732-183X, 6 p.Article

Gemcitabine-associated thrombotic microangiopathyHUMPHREYS, Benjamin D; SHARMAN, Jeff P; HENDERSON, Joel M et al.Cancer. 2004, Vol 100, Num 12, pp 2664-2670, issn 0008-543X, 7 p.Article

Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib: The EVOLVE-1 Randomized Clinical TrialZHU, Andrew X; KUDO, Masatoshi; DORVAL, Etienne et al.JAMA, the journal of the American Medical Association. 2014, Vol 312, Num 1, pp 57-67, issn 0098-7484, 11 p.Article

First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular CarcinomaZHU, Andrew X; GOLD, Philip J; EL-KHOUEIRY, Anthony B et al.Clinical cancer research (Print). 2013, Vol 19, Num 4, pp 920-928, issn 1078-0432, 9 p.Article

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2EDER, Joseph Paul; SHAPIRO, Geoffrey I; MCCALLUM, Stewart et al.Clinical cancer research (Print). 2010, Vol 16, Num 13, pp 3507-3516, issn 1078-0432, 10 p.Article

Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II StudyZHU, Andrew X; SAHANI, Dushyant V; BHARGAVA, Pankaj et al.Journal of clinical oncology. 2009, Vol 27, Num 18, pp 3027-3035, issn 0732-183X, 9 p.Article

Advanced hepatocellular carcinoma : CT perfusion of liver and tumor tissue Initial experienceSAHANI, Dushyant V; HOLALKERE, Nagaraj-Setty; MUELLER, Peter R et al.Radiology. 2007, Vol 243, Num 3, pp 736-743, issn 0033-8419, 8 p.Article